Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer

Fig. 3

Dose proportionality of Ac-K parameters of ENT and the relationship between PK and Ac-K. Profiles of Ac-K levels in CD19+ B cells and plasma ENT concentration. a Dose proportionality of Ac-K levels in CD19+ B cells. Each open circle represents the Ac-K level (change from baseline) in each patient. b Relationship between PK and Ac-K levels in CD19+ B cells. Each open circle, filled circle, and filled square represents each Ac-K level (change from baseline) in Cohort 1, Cohort 2, and Cohort 3, respectively. c Time course of Ac-K levels and plasma ENT concentration in each cohort. Each filled circle represents Ac-K level (median fluorescence intensity) and each open circle represents plasma ENT concentration (ng/mL). In Cohort 3, ENT was not administered at a dosing point marked with an asterisk (*). Each peripheral blood mononuclear cell sample was collected before ENT/EXE administration. Ac-K lysine acetylation, ENT entinostat, EXE exemestane, PK pharmacokinetics

Back to article page